Wang Y, Chen PM, Liu RB. Advance in plasma SEPT9 gene methylation assay for colorectal cancer early detection. World J Gastrointest Oncol 2018; 10(1): 15-22 [PMID: 29375744 DOI: 10.4251/wjgo.v10.i1.15]
Corresponding Author of This Article
Rong-Bin Liu, MD, Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 107, Yanjiang West Road, Yuexiu District, Guangzhou 510120, Guangdong Province, China. liurb3@mail2.sysu.edu.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jan 15, 2018; 10(1): 15-22 Published online Jan 15, 2018. doi: 10.4251/wjgo.v10.i1.15
Advance in plasma SEPT9 gene methylation assay for colorectal cancer early detection
Yu Wang, Pei-Min Chen, Rong-Bin Liu
Yu Wang, Pei-Min Chen, School of Public Health, Guangzhou Medical University, Guangzhou 510180, Guangdong Province, China
Rong-Bin Liu, Department of Ultrasound, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China
Author contributions: Wang Y wrote the paper; Chen PM collected and analyzed the data; Liu RB made substantial contributions to submission, acquiring data, interpreting the results, revising the manuscript and final approval of the version of the article.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Rong-Bin Liu, MD, Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 107, Yanjiang West Road, Yuexiu District, Guangzhou 510120, Guangdong Province, China. liurb3@mail2.sysu.edu.cn
Telephone: +86-20-81332199
Received: October 21, 2017 Peer-review started: October 25, 2017 First decision: November 9, 2017 Revised: November 10, 2017 Accepted: December 6, 2017 Article in press: December 6, 2017 Published online: January 15, 2018
Core Tip
Core tip: The methylated SEPT9 gene has been implicated as a biomarker for colorectal cancer associated with the pathogenesis of colorectal cancer (CRC). In this article, we reviewed the literature on the correlation of SEPT9 gene and colorectal cancer and the theoretical basis of the SEPT9 gene methylation assay. Then, we focused on the diagnostic performance of the SEPT9 gene methylation assay for CRC by analyzing the clinical trial studies and compared that assay with other methods. Finally, we discussed the limitations of the SEPT9 gene methylation assay in clinical application. We hope that this article can provide a comprehensive overview of the progress achieved in the SEPT9 methylation assay for both the basic and clinical sciences.
